COST-PER-RESPONDER ANALYSIS OF BRODALUMAB IN OVERWEIGHT PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
Author(s)
Carlotta De Chiara, MSc1, Filippo Rumi, MA, MSc2, Elena De Medio, MSc1, Eugenio Di Brino, MSc2, Michele Basile, MA, MSc2.
1HEOR & HTA Junior Consultant, Altems Advisory, spin-off dell'Università Cattolica del Sacro Cuore, Rome, Italy, 2Co-Founder & Partner, Altems Advisory, spin-off dell'Università Cattolica del Sacro Cuore, Rome, Italy.
1HEOR & HTA Junior Consultant, Altems Advisory, spin-off dell'Università Cattolica del Sacro Cuore, Rome, Italy, 2Co-Founder & Partner, Altems Advisory, spin-off dell'Università Cattolica del Sacro Cuore, Rome, Italy.
OBJECTIVES: Moderate-to-severe plaque psoriasis is a chronic immune-mediated condition with a significant disease burden and increasing use of biological therapies. Overweight has been associated with reduced therapeutic response to several biologics, making the management of this subpopulation a relevant clinical challenge. Brodalumab, an anti-IL-17 receptor A monoclonal antibody, demonstrated high response rates in the Phase III AMAGINE-2 and AMAGINE-3 trials, with a potentially advantageous efficacy profile in patients with elevated body weight. This study aims to evaluate the economic value profile of brodalumab versus key biologic comparators in overweight patients with moderate-to-severe plaque psoriasis through an integrated cost-per-responder analysis.
METHODS: First, a cost-per-responder analysis was conducted, calculated as the ratio of cumulative treatment cost per patient to the probability of achieving a PASI (Psoriasis Area and Severity Index) response, PASI 75-90-100, at 52 weeks, based on Italian ex-factory prices. Second, a decision tree model was developed to represent the therapeutic pathway, capturing transitions between responder and non-responder health states and estimating direct healthcare costs for each treatment strategy. The analysis adopted the Italian National Health Service (NHS) perspective and included brodalumab, secukinumab and ixekizumab. Robustness was assessed through one-way deterministic sensitivity analysis (DSA) on key model parameters.
RESULTS: Brodalumab showed a competitive cost-per-responder profile compared to the main biologic comparators in the overweight population, driven by high PASI 90-100 response rates observed in this subgroup. The decision tree model quantified differences in total per-patient costs across treatment strategies, accounting for the varying proportions of responders and non-responders and associated care pathways. Sensitivity analyses confirmed the robustness of estimates with respect to the primary sources of uncertainty.
CONCLUSIONS: Brodalumab demonstrates a favorable cost-per-responder profile in overweight patients, representing a potentially cost-effective option within the Italian NHS context. These findings may help inform policy makers' decisions regarding treatment of plaque psoriasis.
METHODS: First, a cost-per-responder analysis was conducted, calculated as the ratio of cumulative treatment cost per patient to the probability of achieving a PASI (Psoriasis Area and Severity Index) response, PASI 75-90-100, at 52 weeks, based on Italian ex-factory prices. Second, a decision tree model was developed to represent the therapeutic pathway, capturing transitions between responder and non-responder health states and estimating direct healthcare costs for each treatment strategy. The analysis adopted the Italian National Health Service (NHS) perspective and included brodalumab, secukinumab and ixekizumab. Robustness was assessed through one-way deterministic sensitivity analysis (DSA) on key model parameters.
RESULTS: Brodalumab showed a competitive cost-per-responder profile compared to the main biologic comparators in the overweight population, driven by high PASI 90-100 response rates observed in this subgroup. The decision tree model quantified differences in total per-patient costs across treatment strategies, accounting for the varying proportions of responders and non-responders and associated care pathways. Sensitivity analyses confirmed the robustness of estimates with respect to the primary sources of uncertainty.
CONCLUSIONS: Brodalumab demonstrates a favorable cost-per-responder profile in overweight patients, representing a potentially cost-effective option within the Italian NHS context. These findings may help inform policy makers' decisions regarding treatment of plaque psoriasis.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE579
Topic
Clinical Outcomes, Economic Evaluation, Health Technology Assessment
Disease
Sensory System Disorders (Ear, Eye, Dental, Skin)